NCT00779428 2015-10-12
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
6 trialsNCT00969917 2015-04-14
Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Infinity Pharmaceuticals, Inc.
Phase 2 Withdrawn
NCT01362400 2014-05-19
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT00564928 2012-12-11
IPI-504-04
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT00817362 2012-12-11
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00627419 2012-12-10
A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Infinity Pharmaceuticals, Inc.
Phase 2 Terminated